Mubadala Backs L-Nutra With $36.5 Million for Abu Dhabi Manufacturing

L-Nutra, a US-based nutri-technology company specialising in fasting and metabolic science, has secured a $36.5 million strategic investment from Mubadala Investment Company. The funding brings the company’s Series D total to $83.5 million and will support the establishment of a manufacturing centre in Abu Dhabi serving the Middle East and North Africa.

Founded in 2009 by longevity researcher Valter Longo and led by Chairman and CEO Dr Joseph Antoun, L-Nutra develops structured, science-backed nutrition programmes that translate fasting research into clinical and consumer applications. Its best-known product is ProLon, a fasting-mimicking diet programme that forms part of the company’s broader portfolio of medical nutrition therapies.

According to the company, the Abu Dhabi joint venture will focus on producing clinically validated nutrition solutions aimed at metabolic health, disease prevention and longevity. The move aligns with Abu Dhabi’s wider push to expand its life sciences and preventive healthcare sectors.

L-Nutra cited results from multiple clinical trials, including recent research conducted with Cedars-Sinai Medical Center and UT Health San Antonio, which reported improvements in weight management, blood sugar levels and increased markers of autophagy following a five-day ProLon protocol.

Mubadala said the investment supports its strategy to position Abu Dhabi as a regional hub for longevity science and advanced nutrition technologies. The sovereign investor manages a global portfolio of around $330 billion and has previously backed companies focused on ageing, regenerative medicine and life-extension research.